The Syneos Health Podcast
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.
Episodes
164 episodes
Project Optimus Series: Operationalizing Dose Optimization
In this episode of The Syneos Health Podcast, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory expectations in the previous episode, we no...
•
17:55
Opportunities Abound for PDTs, with Click Therapeutics
Unlike general health and wellness apps, Prescription Digital Therapeutics (PDTs) are FDA-authorized, prescribed by healthcare professionals, and rigorously studied in clinical trials. With the global PDT market projected to reach $43 billion b...
•
20:27
Unlocking the Black Box of Psychiatric Clinical Research, with Dr. Rishi Kakar of Segal Trials
In this episode, we welcome Dr. Rishi Kakar, Chief Scientific Officer and Medical Director at Segal Trials. Host Andy Moniz<...
•
17:00
Project Optimus Series: The Regulatory Implications of Project Optimus
In this episode of the Syneos Health Podcast, series host Dr. Wael Harb, Vice President of Medical Management at Syneos Health, continues the exploration of FDA's groundbreaking Project Optimu...
•
18:43
CNS Summit Series: Pioneering Patient Advocacy, with Ryan Brooks from CenExel
For our special series celebrating 15 years of innovation with CNS Summit, host Dr. Alexandria Wise sits down with Ryan Bro...
•
14:39
CNS Summit Series: Future-Proofing Clinical Trials
In this episode, Dr. Alexandria Wise speaks with Steve Rosenberg, CEO of uMotif, recorded from the CNS Summit 2024 e...
•
13:06
CNS Summit Series: Pioneering Psychiatry - Behind the Breakthrough KarXT with Dr. Stephen Brannan
In this inspiring look at the progress and potential in psychiatry research, Dr. Alexandria Wise sits down with Dr. Steph...
•
15:59
CNS Summit Series: Decoding Biology to Radically Change the Lives of Patients, with Dr. Najat Khan of Recursion Pharma
In this episode, host Dr. Alexandria Wise sits down with Dr. Najat Khan, Chief R&D Officer and Chief Commercial Officer a...
•
12:20
CNS Summit Series: Schizophrenia, Clinical Trials and Hope, with Dr. David Walling of Cenexel CNS
In this special edition of The Syneos Health Podcast, host Dr. Alexandria Wise celebrates 15 years of innovation with CNS Summit by interviewing
•
13:44
CNS Summit Series: The Future of Immunology and Personalized Health,with Jane Metcalfe of The Human Immunome Project
Recorded from the 15th annual CNS Summit, Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, sits down with
•
13:13
CNS Summit Series: Psychedelics and Beyond, with Kevin Craig of atai Life Sciences
In this episode, Dr. Alexandria Wise celebrates 15 years of innovation at CNS Summit 2024 by sitting down with Kevin Craig<...
•
13:54
CNS Summit Series: Redefining Psychiatry with Science and Compassion, with Dr. David Brown of Community Clinical Research
Join host Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, as he sits down with Dr. Davi...
•
10:11
CNS Summit Series: Patient-Centric Innovation at Scale, with Cristina Duran of Evinova
In this episode, recorded from the floor of the CNS Summit, host Andy Moniz, Vice President of Therapeutic Strategy and Innovation at Syneos He...
•
8:35
CNS Summit Series: Celebrating 15 Years of Innovation with Dr. Amir Kalali of CNS Summit
In this special series of the Syneos Health Podcast, we celebrate 15 years of innovation in collaboration with CNS Summit, a community of innovators and life science industry leaders devoted to discovering better, more efficient ways to advance...
•
12:11
Project Optimus Series: Navigating the Realities of Project Optimus
Launched in 2021 by the FDA's Oncology Center of Excellence, Project Optimus seeks to reshape traditional oncology trial designs and dosing paradigms, shifting from maximum tolerated doses to precision dosing strategies. While the FDA's hope wa...
•
20:51
Psychedelics 3.0: Challenges and Opportunities in an Evolving Field
There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to mee...
•
1:02:37
A Site-Specific Approach to Optimizing Diversity in Oncology Trials
As the biopharma industry strives to ensure that clinical trials reflect the rich diversity of the patient populations they aim to serve, the challenges to make this possible have fallen on the trial sites. In a recent webinar, Syne...
•
42:00
Circulating Tumor DNA: Transforming Oncology Clinical Trials
Use of circulating tumor DNA (ctDNA) – small fragments of DNA that are released into the bloodstream by cancer cells – as a diagnostic tool represents a significant shift toward more precise, personalized cancer care, enhancing both trial effic...
•
20:01
Cashing in on the Currency of Information
Medical science liaisons—or MSLs—within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering. Only they can share certain types of information with a growing number of medical stakeholders. ...
•
34:22
Decoding Gen AI’s Potential to Drive More Effective Clinical Trials
AI is seemingly everywhere now in our lives, including healthcare and drug discovery and development. AI certainly has the potential to enable major advances than development of more effective and safe medical products. And in fact, GenAI has a...
•
31:32
Connecting the Global Dots on Carbon Footprint in Biopharma
The World Economic Forum projects that by 2050, climate change could cause 14 million additional deaths and $12 trillion in global healthcare costs. And this will exacerbate global health inequities with our most vulnerable populations, includi...
•
27:16
Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?
Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living wit...
•
31:58
Unpacking the Role of Adjuvant Therapies in Breast Cancer
Breast cancer is the most common type of cancer among women worldwide, and it can be treated with different modalities, such as surgery, chemotherapy, radiation, hormone therapy and targeted therapy. However, even after the primary treatment, s...
•
28:11
Site and Study Execution for Ophthalmology Trials
This is an exciting time in the development of new medicines to treat both rare and age-related eye diseases. But what is it like in the trenches to develop and deliver clinical trials that evaluate both the safety and efficacy of these potenti...
•
18:34